Ico Girona

Girona 17007

0 studies enrolling now · 11 studies all time

What they study most

Advanced Endometrial Cancer, B-cell Malignancies, Chronic Lymphocytic Leukemia, HER2-Positive Primary Breast Cancer, Mantle Cell Lymphoma; Non-Hodgkin Lymphoma, Metastatic Urothelial Carcinoma, NSCLC, Non Small Cell Lung Cancer, Non-small Cell Lung Cancer, OVARIAN CANCER, PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC, Pancreatic Cancer

Studies at this site

• Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06) — Running, not enrolling
• A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation — Running, not enrolling
• A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05) — Running, not enrolling
• A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer — Stopped early
• Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205) — Stopped early
• Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Participants With B-cell Malignancies — Running, not enrolling
• A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia — Completed
• A Study to Compare Ociperlimab Plus Tislelizumab Versus Durvalumab Following Concurrent Chemoradiotherapy (cCRT) in Participants With Stage III Unresectable Non-Small Cell Lung Cancer — Stopped early
• GEN1046 in Combination With Anticancer Agents for the Treatment of Advanced Endometrial Cancer — Withdrawn before enrolling
• ABTL0812 in Combination With FOLFIRINOX for First-line Treatment of Metastatic Pancreatic Study — Completed
• A Clinical Study of Cobimetinib Administered in Combination With Niraparib, With or Without Atezolizumab to Patients With Advanced Platinum-sensitive Ovarian Cancer — Completed